Plain-English translation of NCT05389423 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing — a newer type of immunomodulatory drug — combined with standard chemotherapy to treat non-Hodgkin lymphoma in people living with HIV. The medication is designed to boost your immune system's ability to fight cancer cells while the chemotherapy directly attacks the lymphoma. Researchers believe this combination may work better than chemotherapy alone, especially for lymphomas associated with the Epstein-Barr virus, which are more common and more aggressive in people with HIV.
People living with HIV face a significantly higher risk of developing lymphoma compared to the general population, and these cancers often behave differently and more aggressively. Standard chemotherapy treatments used for lymphoma in HIV-negative patients may not be optimal for people with HIV, so this trial is testing whether adding this medication — which helps restore immune function — can improve outcomes for this underserved patient population.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive the new medication combined with chemotherapy drugs given intravenously (through an IV). The study has two phases: first, researchers will test increasing doses of the medication to find the safest effective dose, then they will enroll more participants at that dose level. You will need to visit the clinic regularly for treatment infusions, blood tests, and scans to monitor how your lymphoma is responding. You will also need to take daily low-dose aspirin or another blood-thinning medication, stay on your HIV medications, use contraception if applicable, and enroll in a mandatory safety monitoring program for the medication.
AI-generated summary from trial data · Jul 2, 2026 · Not medical advice
United States